DARE

1.99

6.99% 0.13

Vorhandelsmarkt: 1.96 -0.03 -1.51%

Dare Bioscience Inc (DARE)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.86

Offen:

24-Stunden-Volumen:

602.55K

Relative Volume:

4.37

Marktkapitalisierung:

$28.44M

Einnahmen:

Nettoeinkommen (Verlust:

$-30.16M

KGV:

-5.8529

EPS:

-0.34

Netto-Cashflow:

$-39.49M

1W Leistung:

+14.04%

1M Leistung:

+9.34%

6M Leistung:

-37.62%

1J Leistung:

-40.42%

1-Tages-Spanne:

$1.93

$2.12

1-Wochen-Bereich:

$1.71

$2.12

52-Wochen-Spanne:

$1.61

$9.19

Dare Bioscience Inc Stock (DARE) Company Profile

Firmenname

Dare Bioscience Inc

Sektor

Healthcare (1124)

Branche

Biotechnology (627)

Telefon

858-926-7655

Adresse

3655 NOBEL DRIVE, SAN DIEGO, CA

Mitarbeiter

Twitter

@DareBioscience

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

DARE's Discussions on Twitter

Vergleichen Sie DARE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DARE Dare Bioscience Inc	1.99	26.58M	0	-30.16M	-39.49M	-0.34
VRTX Vertex Pharmaceuticals Inc	444.64	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	726.21	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	890.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	404.46	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	189.85	41.41B	447.02M	-1.18B	-906.14M	-6.1812

Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten

Dec 10, 2025

Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus

Dec 10, 2025

Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative

Dec 10, 2025

Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan

Dec 10, 2025

Dec 02, 2025

Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada

Dec 02, 2025

DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus

Dec 02, 2025

Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada

Dec 02, 2025

Dec 01, 2025

Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus

Dec 01, 2025

Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com

Dec 01, 2025

Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com

Dec 01, 2025

Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView

Dec 01, 2025

Daré Bioscience (NASDAQ: DARE) regains Ovaprene rights after Phase 3 interim data - Stock Titan

Dec 01, 2025

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Sahm

Dec 01, 2025

Nov 25, 2025

H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛

Nov 25, 2025

Nov 24, 2025

Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria

Nov 24, 2025

DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus

Nov 24, 2025

Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times

Nov 24, 2025

Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com

Nov 24, 2025

Nov 22, 2025

Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next? - Defense World

Nov 22, 2025

Nov 15, 2025

Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN

Nov 15, 2025

Nov 14, 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

Nov 14, 2025